Avid Bioservices, Inc.

About Avid

From DNA to IND to Commercial, Avid is the U.S.-Based Biologics CDMO Partner for Every Stage
Avid Bioservices is a leading U.S.-based mammalian cell culture contract development and manufacturing organization with decades of biologics manufacturing experience and a track record of regulatory success. Avid provides integrated cell line development, process development, analytical development, and CGMP biologics manufacturing from DNA to IND to commercial supply.

Integrated Solutions Across the Biologics Development Lifecycle
From end to end, Avid provides integrated mammalian cell culture development and CGMP manufacturing designed to accelerate timelines, reduce risk, and simplify execution from early development through commercial supply.

Biologics Development is Complex; A CDMO Partner Shouldn’t Be

A trusted partner for biopharmaceutical innovators worldwide, Avid combines manufacturing, operational discipline, and a transparent partnership model to reduce risk and simplify execution. Agility, quality, proven ability to navigate complex global regulatory landscapes and a steadfast FDA record make Avid the best choice for a U.S.-based biologics CDMO. Decades of biologics manufacturing experience demonstrate trust, true partnership and a track record of regulatory success.

U.S.-Based Facilities Designed for Biologics

Avid’s FDA-inspected CGMP biologics facilities in California provide secure, domestic biologics manufacturing aligned with evolving regulatory and supply chain expectations.

Operational Excellence

The Avid way of working drives disciplined execution, continuous improvement, and predictable timelines.

True Program Partnership

Avid’s dedicated cross-functional teams provide direct access to scientific and manufacturing leaders from development to commercial supply. Avid senior scientists participate in team calls from week one. Tech transfer is what Avid does every day – not something theoretical or squeezed in. Confidence and communication are built into every step.
Integrated to Reduce Friction

Consistent instrumentation across process development and manufacturing simplifies tech transfer and strengthens process consistency. Switching CDMOs at Phase 3 is the single highest-stakes manufacturing decision a company will make. Avid has executed tech transfers across scale-up for the last decade, with trust and a proven track record.
Quality Without Compromise

Quality is embedded across every stage of development and manufacturing. Avid’s CGMP facilities operate under rigorous regulatory standards to support clinical and commercial biologics programs with confidence. Avid ensures regulatory-ready operations, robust quality systems, and CMC & regulatory support.
Partnership Built Around Each Program

Avid partnership means direct access, aligned teams, and shared accountability. Scientists, engineers, and manufacturing leaders work alongside each partner from development through commercial supply with transparency at every step.

o Dedicated program teams

o Direct Access to expertise

o Aligned form Day one

A U.S.-Based Biologics CDMO Partner for Every Stage

From DNA to IND to Commercial, Avid is the U.S.-based biologics CDMO partner for every stage. With you, every molecule of the way.

Avid By the Numbers:  

o 650+ batches manufactured

o 30+ years manufacturing biologics  

o 275+ commercial batches globally  

o 7 commercial products  

o 10 successful pre-approval/pre-license inspections across major regulatory agencies

Responsible Manufacturing, Sustainable Growth

Avid is committed to operating responsibly, supporting environmental stewardship, operational efficiency, and long-term sustainability across our manufacturing platform.

Ready to Move Your Molecule Forward?

From DNA to IND to commercial supply, Avid Bioservices provides U.S.-based mammalian cell culture development and CGMP biologics manufacturing built around partnership, operational excellence, and predictable execution.

With you, every molecule of the way.

Let’s build what’s next – together.

14191 Myford Road
Tustin, California 82780
NEWS
40 Under 40 honorees’ accomplishments include co-developing the world’s first synthetic biology programming language for mRNA and co-founding and leading a company acquired for $700 million up-front and up to $1.225 billion in total consideration.
With the Thanksgiving season upon us, there are many reasons for biopharma and life sciences companies to say thanks, including for new leaders.
Biopharma and life sciences companies, such as Seraxis, Verily and Vaxart, tap new members to bolster their leadership teams in roles like CMO, CTO, CCO, and more.
Biopharma and life sciences companies bolster their executive teams and board with these Movers & Shakers.
It’s been a busy week for biopharma companies to name a chief executive officer. Over the past week, multiple companies have selected individuals to hold the top spots and guide the growth strategies of their companies.
IN THE PRESS
JOBS